Research programme: cannabinoid-based microencapsulated cell therapies - PharmaCyte Biotech

Drug Profile

Research programme: cannabinoid-based microencapsulated cell therapies - PharmaCyte Biotech

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator Nuvilex
  • Developer PharmaCyte Biotech; University of Northern Colorado
  • Class Cannabinoids; Cell therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Brain cancer; Pancreatic cancer
  • Research Cancer

Most Recent Events

  • 01 Sep 2016 Preclinical trials in Brain and Pancreatic cancer in USA (Parenteral)
  • 15 Jun 2015 The University of Northern Colorado obtains a Schedule 1 license from the U.S. Drug Enforcement Agency (DEA) to continue development of cannabinoid-based microencapsulated therapies
  • 16 Mar 2015 Early research in Brain cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top